Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Intravenous ferric carboximaltose in heart failure with preserved or intermediate ejection fraction
Session:
Painel 2 - Insuficiencia Cardiaca 6
Speaker:
Vanessa Novais de Carvalho
Congress:
CPC 2020
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters
FP Number:
---
Authors:
Vanessa Carvalho; Jacome Morgado; Ines Rodrigues; Pedro Moraes Sarmento
Abstract
<p>Iron deficiency (ID), regardless ejection fraction (EF), is prevalent in heart failure (HF) and contributes to the impairment of functional capacity, to poor quality of life and increased mortality in HF patients. ID identification and its correction are currently recommended in the guidelines for the treatment of HF with reduced ejection fraction (HFrEF). However, evidence of ID correction beneficial effects is lacking in patients with HF and preserved EF (HFpEF) or mid-range EF (HFmrEF). Objective: Evaluate the influence of iron therapy on NYHA class and NTproBNP in ID symptomatic HFpEF patients. </p> <p>Methods: Among patients submitted to ID correction with ferric carboximaltose (FCM) between 2015 and 2016, patients with HFpEF and HFmrEF, with and without anemia were identified and compared with patients with HFrEF treated in the same period. Between 2015 and 2018, patient outcome was assessed, namely NYHA class, N-terminal portion of type B natriuretic peptide (NTproBNP), and renal function at three and six months after treatment. Results: 52 patients with HF and ID were selected: 69% men, 86±5 years. 65,4% had HFpEF and HFmrEF and 34.6% HFrEF. 90.4% of patiens had anemia. Functional ID was present in 13% and 23 of HFrEF and HFpEF/HFmEF, respectively. Patients with HFpEF/ HFmrEF had less coronary artery disease (44% and 78%) and less diabetes mellitus (26% and 44%). No differences were observed in the other comorbidities. In the follow-up study of patients undergoing FCM, we identified 56 patients. 83% had absolute ID and 75% anemia. 50% were in NYHA class II and 46% in class III. NTproBNP was 6492pg/mL and eGFREPI was 47.8mL/min/m<sup>2</sup>. At three and six months, 59% and 61% patients were in NYHA class II and 39% and 37% in class III. NTproBNP was 5331pg/mL and 4000pg/ mL, and eGFREPI was 45.8mL/min/m<sup>2</sup>and 45.8mL/min/m<sup>2</sup>.</p> <p>Conclusion: ID is by itself underestimated in clinical practice. At three and six months after FCM treatment, we found a functional improvement in patients, assessed by NYHA class, as well as a reduction in NTproBNP levels.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site